특허권공유확인등
1. Defendant (Counterclaim Plaintiff) Co., Ltd. and Defendant (Counterclaim Plaintiff Co-Litigation Intervenor) who were brought in the trial after the second return.
1. Basic facts
A. The defendant company is a company established on September 21, 1972 for the purpose of research and development of whites, manufacture, manufacture, and sale of medicines (the trade name at the time of establishment is D and the trade name was changed on September 3, 2004).
(2) From March 21, 2001, Defendant C served as the representative director of the Defendant Company. 2) The Plaintiff obtained a master’s degree from N University Health Graduate School in 1980, and from P in 1984, the Plaintiff obtained a doctor’s degree from P in 1984.
The Plaintiff, from around 1998 when he worked for E Co., Ltd. (hereinafter “E”), was in charge of contact with F after first contacted with F (F) of the Netherlands (hereinafter “F”) with regard to the development of aviation cancer and was working for G Co., Ltd. (hereinafter “G”).
In addition, from March 21, 2001 to March 21, 2004, the Plaintiff served respectively as the auditor of the Defendant company, and from March 21, 2004 to March 21, 2006 as the director of the Defendant company.
B. On February 25, 2001, the Defendant Company and H’s development agreement 1) concluded with H on February 25, 2001 with the Plaintiff’s introduction of the Plaintiff on the following terms: “The Agreement on the Development of Airbrance Using AB compound” (hereinafter “the “Agreement”) as an An An Ani-rumor” (hereinafter “the instant development agreement”).
Research and development has been concluded. Research and development is conducted in three stages. - One step (20 weeks scheduled, expected total expenses: 95,00 am): Test on the efficacy test, etc. in the cell line of the human body of a human body selected chemical and preparation for and receipt of PC, decision on the continuation/suspension for two stages - Two stages (23 weeks scheduled, expected total expenses: 1,612,000 am): Development and verification of analysis methods for the detection of non-explosion in the previous and clinical samples; 3 stages (104 weeks scheduled, expected total expenses: 1,545,00 am): Decision on the continuation/suspension of the terminal patient; 45 pams for cancer patients.